公开(公告)号：US20250019369A1

公开(公告)日：2025-01-16

申请号：US18708486

申请日：2022-11-09

Applicant: Cerevance, Inc.

Inventor： Roland Burli ,  Kevin Doyle

IPC: C07D403/14 ,  A61K31/4439 ,  A61K31/506 ,  C07D401/04 ,  C07D403/04 ,  C07D417/04

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof: wherein Het, X1, X2, L, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly for use in treating disorders associated with CD38 activity.

公开(公告)号：US20240158385A1

公开(公告)日：2024-05-16

申请号：US18275862

申请日：2022-02-08

Applicant: Cerevance, Inc.

Inventor： Roland Werner Burli ,  Kevin Doyle ,  Martin Teall

IPC: C07D413/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04

CPC classification number: C07D413/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof Formula (I) wherein R2, R3, R4, X1, X2, X3 and X4 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly for use in treating disorders associated with KCNK13 activity.